Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

# Mitochondrial Heterogeneity in Cancer: A Review

**Running title**
Mitochondrial Variability in Cancer

**1Dr. Sharique Ahmad, 2Dr Oswin Harris, 3Priyanka Sharma, 4Dr. Nishi Tandon, 5Ms. Subuhi Anwar, 6Mr. Pankaj Sachdeva**

1Professor, Department of Pathology, Era's Lucknow Medical College And Hospital, Era University, Sarfarzganj, Hardoi road, Lucknow, Uttar Pradesh, India-226003.

2Lecturer, Department of Anatomy, American University of Barbados School of Medicine, Barbados, Wildey, Saint Michael, Barbados, PIN - BB11100.

3Junior Resident, Department of Pathology Era's Lucknow Medical College And Hospital, Era University, Sarfarzganj, Hardoi road, Lucknow, Uttar Pradesh, India-226003.

4Professor, Department of Pathology, Era's Lucknow Medical College And Hospital, Era University, Sarfarzganj, Hardoi road, Lucknow, Uttar Pradesh, India-226003.

5Research Assistant, Department of Pathology, Era's Lucknow Medical College And Hospital, Era University, Sarfarzganj, Hardoi road, Lucknow, Uttar Pradesh, India-226003.

6Medical Student, AUB School of Medicine,Wildey, Bridgetown, Saint Michael, BB11100, Barbados

**Corresponding Author:**
**Ms. Subuhi Anwar,**
Research Assistant, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Hardoi Road, Lucknow- 226003, Uttar Pradesh, India.

***(Received: 16 November 2024 Revised: 20 December 2024 Accepted: 04 January 2025)***

**KEYWORDS**

Mitochondrial heterogeneity, Cancer, Diagnosis, Therapy, Treatment resistance

**ABSTRACT:**

Mitochondria are important organelles in nucleated eukaryotic cells that control energy metabolism, redox balance, and apoptosis. Mitochondrial dysfunction, caused by TCA cycle enzyme abnormalities, mitochondrial DNA genetic mutations, a faulty mitochondrial electron transport chain, oxidative stress, or incorrect oncogene and tumor suppressor signaling, has been observed in a variety of human cancers. Emerging research emphasizes the significance of mitochondrial diversity in cancer initiation, progression, and therapy response. This review explores the various elements of mitochondrial variability in cancer, to understand the genetic, functional, and morphological variants. Mechanistically, mitochondrial DNA mutations, metabolic reprogramming, and dynamic changes in mitochondrial shape all contribute to this diversity. Furthermore, we investigate how mitochondrial heterogeneity influences tumor growth, metastasis, and resistance to treatment.A comprehensive and methodical search technique was utilized in the methodology to locate studies across multiple databases. A systematic search was conducted utilizing combinations of keywords such as mitochondrial heterogeneity, Cancer and related terms to access PubMed/MEDLINE, Scopus, Web of Science, and other credible academic databases.Therapeutically, targeting mitochondrial heterogeneity offers intriguing pathways for cancer treatment, with treatments cantered on modifying mitochondrial metabolism, restoring dynamics, and exploiting dysfunction-related vulnerabilities. Understanding mitochondrial variability has the potential to lead to novel therapeutic approaches and individualized treatment techniques, ultimately improving patient outcomes.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

**Introduction**

Mitochondria are double-membrane-bound, semi-autonomous intracellular organelles that have an outer membrane, an inner membrane that is highly folded (called a crista), an inner membrane that surrounds a matrix region, and an intermembrane gap that connects the two membranes [1]. Numerous mitochondria can occupy up to 25% of the cytoplasm in a typical cell, which might have hundreds or thousands of them. The center of lipid, glutamine, and glucose metabolism is the mitochondria [2]. Mitochondria's principal role is to promote aerobic respiration and the TCA cycle via oxidative phosphorylation. This is accomplished by creating ATP via the mitochondrial respiratory chain, which provides the energy required for cell survival. [3, 4] The presence of mitochondrial DNA (mtDNA), a double-stranded oval genetic material that is supercoiled that codes for proteins, rRNAs, and tRNAs necessary for oxidative phosphorylation and electron transport, They also have their genetic repair processes, is one of the organelles' distinctive features [3,5,6]

Through the metabolic reprogramming of cancer cells, mitochondria may contribute to the formation of the malignant phenotype in at least five different ways. First, it is well established that many diseases are linked to mitochondrial DNA abnormalities, mostly as a result of changes to electron transport chain (ETC) subunits [3]. For instance, mutations in the D-loop area of Complex I have been linked to subsets of prostate and hepatocellular carcinomas, while succinate dehydrogenase (SDH; Complex II) alterations have been found in certain neurological malignancies [4,5,6]. Second, the most significant trigger for the development of cancer and its advancement to malignancy is oxidative stress brought on by reactive oxygen species (ROS) [7].

As a consequence of oxidative respiration, superoxide is released by mitochondria, which is the primary source of ROS [8]. Either the TCA cycle or the ETC can produce mitochondrial ROS (mtROS) [9]. Owing to their high reactivity, At low concentrations, ROS can be dangerous for cellular macromolecules [10] and act as intracellular signaling agents that regulate metabolic pathways [11, 12]. Because of their altered antioxidant capabilities and enhanced metabolic activities, cancer cells frequently have elevated ROS levels [13]. Third, apoptosis and necrosis, among other forms of cell death, are directly regulated by mitochondria [14][15].

B-cell lymphoma-2 (Bcl-2) proteins bind to the voltage-dependent anion channel (VDAC) and accelerate its opening and cytochrome c release, which causes apoptosis in mitochondria [16]. Accordingly, these proteins function as oncogenic or oncosuppressive triggers, which aid in the development of cancer and treatment resistance [17][18]. Often overexpressed in human cancer, myeloid leukemia cell differentiation protein-1 (MCL-1) is a member of the Bcl-2 family that inhibits apoptosis and is associated with tumor aggressiveness [19]. They have found MCL-1 and Bcl-xL in different mitochondrial subcompartments. They oppose the pro-apoptotic Bcl-2 family members when they are present in the outer mitochondrial membrane (OMM) [20]. By preserving the integrity of the inner mitochondrial membrane (IMM) and promoting the formation of ATP-synthase oligomers at the ETC, they control mitochondrial homeostasis and bioenergetics when present in the mitochondrial matrix [17]. Mitochondria also control necroptosis, a controlled form of necrosis that depends on the mitochondrial permeability transition and necessitates the generation of mtROS [21]. Fourth, metabolic reprogramming also includes many mutations in genes that encode TCA cycle enzymes, which promote malignant transformation [22].

In fact, some TCA cycle intermediates, such as fumarate, succinate, aspartate, and D-2-hydroxyglutarate (2HG), a de novo metabolite resulting from mutations of isocitrate dehydrogenases (IDHs), have strong pro-carcinogenic effects when they accumulate in cells following genetic mutations and/or cancer-associated changes in protein expression [23]. Fifth, a feature common to all malignancies is consistent cellular growth caused by several molecular alterations. Constitutive telomerase synthesis, which stops telomere degradation, is one of these modifications that maintain telomere length [24]. It has been shown that in response to oxidative stress, telomerase reverse transcriptase (TERT) migrates from the nucleus to the mitochondria, preserving mitochondrial functions and lowering oxidative stress, protecting nuclear DNA (nDNA) and mitochondrial

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

DNA (mtDNA) from oxidative damage and apoptosis [25][26]. TERT was also seen to build up in the mitochondria of the brain cells of mice following rapamycin treatment and dietary restriction [27].

**Aim:** This study examines the various elements of mitochondrial variability in cancer,

**Objectives:** To understand genetic, functional, and morphological variants. Mechanistically, mitochondrial DNA mutations, metabolic reprogramming, and dynamic changes in mitochondrial shape all contribute to this diversity. Furthermore, we investigate how mitochondrial heterogeneity influences tumor growth, metastasis, and resistance to treatment.

**Methodology:** A comprehensive and methodical search technique was utilized in the methodology to locate studies across multiple databases. A systematic search was conducted utilizing combinations of keywords such as mitochondrial heterogeneity, Cancer and related terms to access PubMed/MEDLINE, Scopus, Web of Science, and other credible academic databases.

**Mitochondrial Heterogeneity in Cancer:**

Cancer cells exhibit morphological, functional, and genetic features of mitochondrial heterogeneity, all of which contribute to the heterogeneity and growth of tumors. Comprehending the many aspects of mitochondrial variability is essential in order to unravel the underlying mechanisms and formulate focused therapeutic approaches.

Mitochondria play a significant role in the development of cancer. The three primary stages of cancer development are defined by the involvement of mitochondria. The diagram illustrates how mitochondria function in these stages:

(1) The production of reactive oxygen species (ROS) can potentially damage nuclear and mitochondrial DNA, leading to oncogenesis.

(2) Metabolic plasticity causes increased progression of tumors and stemness.

(3) Biogenesis and high mitochondrial turnover cause epithelial-mesenchymal transition (EMT) and metastatic dissemination.




**Fig 1:**Showing cancer progression

**Morphological Heterogeneity:** Cancer cells' mitochondrial morphology varies remarkably, from long, linked networks to broken, punctate structures. Recent research has clarified the complex link between cellular functions and mitochondrial morphology, emphasizing the part fusion-fission dynamics play in preserving cellular flexibility and mitochondrial homeostasis (8). The morphological variability seen in

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

cancer cells is a result of dysregulated fusion-fission processes, which also impact the distribution of organelles, bioenergetic efficiency, and stress response (9).

- **Functional Heterogeneity:** Different metabolic pathways, redox conditions, and apoptotic signals are reflected in the varied mitochondrial functions seen in cancer cells. Cancer is characterized by metabolic reprogramming, which causes changes in mitochondrial metabolism that prefer glycolysis to oxidative phosphorylation (OXPHOS), even in the presence of oxygen. (the Warburg effect) (10). This metabolic flip produces more biomass and supplies metabolic intermediates necessary for the growth and multiplication of tumors. Furthermore, dysregulated generation of reactive oxygen species (ROS) is caused by abnormal mitochondrial function, which exacerbates oxidative stress and encourages genomic instability (11).
- **Genetic Heterogeneity:** Mutations in mitochondrial DNA (mtDNA), which codes for vital elements of the respiratory chain and mitochondrial ribosomes, are the cause of mitochondrial genetic heterogeneity in cancer cells. A growing body of research links mtDNA mutations to tumor development, resistance to treatment, and carcinogenesis. Certain mtDNA mutations have been linked in recent research to aggressive tumor characteristics, metabolic rewiring, and altered mitochondrial function (12). Furthermore, mitochondrial malfunction and phenotypic heterogeneity in cancer cells are caused by mtDNAheteroplasmy, or the coexistence of wild-type and mutant mtDNA.

➢ **Mechanisms Underlying Mitochondrial Heterogeneity:** Mitochondrial heterogeneity in cancer is caused by several molecular pathways such as:

- mtDNA Mutations**:** Somatic mtDNA mutations affect the function of the respiratory chain, the generation of ROS, and cellular metabolism. These changes are linked to mitochondrial malfunction and the advancement of tumors (13)
- Dysregulated fusion-fission processes cause disruptions to mitochondrial shape and distribution, which in turn affects cellular bioenergetics, stress responses, and decisions about the destiny of individual cells (14).
- Metabolic Reprogramming: Cancer cells' mitochondrial function and heterogeneity are shaped by oncogenic signaling pathways that cause metabolic rewiring, which promotes glycolytic metabolism and suppresses OXPHOS (15).

Mitochondrial heterogeneity plays a vital role in promoting tumor heterogeneity, plasticity, and adaptability to microenvironmental stressors. This allows cancer cells to endure and multiply under unfavorable circumstances. The presence of diverse phenotypic subpopulations with unique metabolic profiles, susceptibilities to treatment, and propensity for metastasis is made possible by the heterogeneous mitochondrial populations found in malignancies (16). Furthermore, cancer cells' ability to adjust to changes in oxygen availability, nutritional availability, and metabolic needs in the tumor microenvironment is made possible by their mitochondrial flexibility, which encourages the growth of tumors and resistance to treatment.

➢ **Factors Contributing to Mitochondrial Heterogeneity**

Numerous variables, such as genetic mutations, changes in fusion-fission dynamics, metabolic reprogramming, and environmental impacts, contribute to mitochondrial heterogeneity in cancer. Each of these elements influences the many mitochondrial phenotypes seen in tumor cells, which in turn affects the course of the tumor, the effectiveness of treatment, and the prognosis of patients.

- Genetic Mutations: The main cause of mitochondrial heterogeneity in cancer is somatic mutations in mitochondrial DNA (mtDNA). Replication mistakes and oxidative damage cause tDNA mutations to accumulate over time, impairing mitochondrial biogenesis and respiratory chain complex function (17). Tumor heterogeneity and aggressiveness are exacerbated by these alterations, which impact energy metabolism, ROS generation, and mitochondrial function. Recent research has shown particular mtDNA mutations linked to different forms of cancer, emphasizing their function in the development and

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

spread of tumors (18). For example, aggressiveness and resistance to therapy in prostate cancer have been linked to mtDNA mutations in the MT-COI (cytochrome c oxidase subunit I) gene (19).

- Fusion-Fission Dynamics: When fusion-fission dynamics are dysregulated, it affects signaling pathways, cellular bioenergetics, and stress responses by changing the shape and distribution of mitochondria. Mitofusins (MFN1/2) and dynamin-related protein 1 (DRP1) are examples of fusion and fission proteins whose abnormal expression in cancer cells modifies the dynamics of the mitochondria.20). Fragmented, elongated, or linked structures are the hallmarks of heterogeneous mitochondrial networks, which are formed when fusion-fission processes go out of balance. These changes in morphology have an effect on the position and purpose of the mitochondria, which influences the migration, survival, and multiplication of cells. Targeting the fusion-fission machinery has been shown in studies to modify mitochondrial heterogeneity and increase the sensitivity of cancer cells to treatment (21).
- Metabolic Reprogramming: Cancer is characterized by metabolic reprogramming, which modifies nutrition utilization and mitochondrial metabolism. It is driven by oncogenic signaling pathways. A common metabolic trait seen in many cancer cells is the Warburg effect, which is defined by elevated glycolysis and decreased OXPHOS (22). Tumor development, invasion, and metastatic potential are influenced by metabolic heterogeneity, which is a result of dysregulated mitochondrial metabolism. Furthermore, metabolic modifications let cancer cells endure in nutrient-poor and hypoxic environments, which accelerates tumor growth and resistance to treatment. Targeting nutrition sensing pathways and mitochondrial metabolism are two examples of the metabolic vulnerabilities in cancer cells that have been found in recent research and may be used for therapeutic intervention [22, 23]
- Environmental Influences: Through modifications in nutrition availability, oxygen levels, and extracellular signals, the tumor microenvironment has a significant impact on mitochondrial variability. Solid tumors frequently exhibit hypoxia, which modifies mitochondrial metabolism and function and triggers adaptive responses in cancer cells (24). Furthermore, the tumor microenvironment's metabolic interaction between stromal cells and cancer cells affects the dynamics and heterogeneity of mitochondria. For instance, the lactate that glycolytic cancer cells produce can stimulate OXPHOS in nearby cancer cells, encouraging metabolic symbiosis and the formation of tumors (25). Moreover, environmental stresses like radiation and chemotherapy cause damage to and functioning of the mitochondria, which selects for phenotypes of mitochondria that are resistant to treatment.




**Fig 2:** Mitochondria play a vital role in normal cell function (A) and abnormal cells (B). They generate ATP for the cell's metabolic processes. In abnormal cells, they can contribute to the development of diseases like cancer etc.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

Understanding the complex interactions among these variables is crucial to understanding the causes behind mitochondrial heterogeneity in cancer and creating focused treatment plans. Novel strategies to overcome medication resistance and enhance patient outcomes might be developed by focusing on mitochondrial vulnerabilities and adjusting cellular metabolism.

- **Implications for Tumor Progression**:

Cancer-related mitochondrial heterogeneity Cancer is caused by the fast growth of aberrant cells that build up into tumors that are larger than normal and have the potential to metastasize to other organs (26). It is evident that the flexibility of cancer cells is influenced by cancer heterogeneity. According to this perspective, the tumor microenvironment primarily influences cancer plasticity through epigenetic alteration (27, 28).Nonetheless, there is mounting evidence that the heterogeneity of cancer is significantly influenced by mitochondrial heterogeneity (29, 30). Thyroid, colorectal, and kidney cancers are among the tumor types where age-related accumulation of mtDNA mutations has been reported (31, 32). While ND4 is usually mutated in lung and prostate cancers, the ND5 gene, which is present in mtDNA, is more commonly altered in most cancer cells. Mutations were found in more than 85% of the mtDNA recovered from 38 different cancer types and 21 cancer tissues.Sequencing of the mtDNA mutation in tumorepithelial cells revealed that 330 44% of mtDNA mutations in adenomas and 85% of mtDNA mutations in adenocarcinomas were tumor specific. Additionally, comparable changes have been discovered in the mtDNA of normal crypts, suggesting that mtDNA heterogeneity in normal crypts may provide a selective metabolic advantage during carcinogenesis (33,34), studies that concentrate on the mitochondrial proteome provide compelling evidence of mitochondrial variability in cancer. (35, 36). A number of mitochondrial proteins, such as PRDX3 and SOD2, have been connected to redox pathways and ROS. They have also been used to differentiate between the nonmetastatic and metastatic cell sublines of nasopharyngeal carcinoma (NPC) (37, 38, 39). Suppression of mitochondrial PRDX3 in the ROS pathway enhanced the mobility capacity of NPC metastatic cancer cells (40).

Additionally, a number of enzyme profiles linked to the TCA and OXPHOS pathways were substantially different in OC cells as compared to platinum-resistant cell sublines, as shown by the mitochondrial proteomic analysis of human ovarian cancer (OC) cells in comparison to drug-resistant cell sublines (41,42), or human OC tissues (43). A few of these enzymes play a key role in the development and upkeep of tumors.

IDH, for instance, is overexpressed in OC tissues and is involved in growth and proliferation, indicating that mitochondrial heterogeneity plays a part in drug resistance in cancer cells (44, 45, 46 ).It's interesting to note that treatments that target mitochondrial IDH have been used in clinical settings (48).Studies on the human OC mitochondrial phosphoproteome found that 48 mitochondrial proteins exhibited different degrees of phosphorylation in OC and paracarcinoma tissues (49, 50). Human OC and NPC mitochondrial proteome analysis has yielded good models for investigating treatment targets in a variety of cancers (51). The Warburg effect, which causes ATP generation to switch from oxidative phosphorylation to glycolysis even at normal oxygen concentrations, underpins a critical metabolic phenotype observed in cancer cells. (52, 53) It has long been assumed that mitochondrial defects that limit the efficient oxidation of glucose carbon into carbon dioxide are responsible for this metabolic reprogramming in cancer cells (54, 55). Recent research, however, has revealed that the majority of mitochondria in cancer cells are reprogrammed to act as biosynthetic organelles, free of functional defects, and that these organelles are required for tumorigenesis and metastasis (56, 57, 58). In terms of carcinogenesis, SDH deficits cause 10-70% of inherited paragangliomas and 10-30% of pheochromocytomas. Hereditary paragangliomas and pheochromocytomashave also been found to have heterogeneous SDH subunit expression (59).When SDH is suppressed, mitochondrial Complex II activity decreases and ROS production increases, resulting in high angiogenic factor expression in paraganglioma cells (60).

Fumarate hydratase (FH) heterogeneity is important in tumor formation in aggressive forms of renal cell carcinoma, as well as in many cutaneous and uterine leiomyomas.As FH is a key enzyme of the TCA cycle, its variability in renal cancer cells causes a metabolic

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

shift from the TCA cycle to a linear metabolic pathway that begins with glutamine intake and ends with bilirubin excretion in mitochondria (61). Furthermore, cancer spread has been associated to increased mitochondrial redox activity (62). Cancer cells' invasiveness and survival have been linked to increased mitochondrial membrane potential (63). According to current research, mitochondrial heterogeneity promotes the spread and metastasis of cancer cells(64).Breast cancer metastasis was promoted by heterogeneity in mitochondrial PHGDH protein, and circulating cancer cells in the same host as breast cancer demonstrated higher mitochondrial biogenesis and respiration when compared to cancer cells in the primary tumors (65) In various cancer metastasis models, including melanoma and oral squamous cell carcinoma, invasion by leader cells has been associated to an increase in translation rate and mitochondrial membrane potential (66).

➢ **Therapeutic Targeting of Mitochondrial Heterogeneity in Cancer:**

- **Current Therapeutic Strategies:** a. Mitochondrial Metabolism Inhibitors: As potential anticancer drugs, small molecule inhibitors that specifically target key enzymes including the electron transport chain (ETC) and tricarboxylic acid cycle (TCA) that are involved in mitochondrial metabolism, have shown promise. For instance, complex I and III inhibitors, such as metformin and antimycin A, impair mitochondrial respiration and cause cytotoxicity in cancer cells (67). Moreover, mitochondrial ATP synthase inhibitors, like oligomycin, prevent the synthesis of ATP, endangering the viability and growth of cells.
- **ROS Destroyers:** Reactive oxygen species (ROS) scavengers are a possible therapeutic strategy because they promote carcinogenesis and therapy resistance. Excess reactive oxygen species (ROS) are neutralized by antioxidants such vitamin C and N-acetylcysteine (NAC), which lower oxidative stress and stop the growth of cancer cells (68).
- **Mitochondrial Dynamics Modulators:** Treating cancer with compounds that target the fusion and fission processes in the mitochondria presents new therapeutic options. Inhibitors of the essential regulator of mitochondrial fission, dynamin-related protein 1 (DRP1), for example, impair cancer cell proliferation and metastasis (69). Conversely, activators of mitochondrial fusion promote mitochondrial network integrity and cellular fitness, reducing tumor aggressiveness.

➢ **Benefits and Challenges:** Targeting mitochondrial heterogeneity in cancer treatment has several possible advantages, such as:

- Cancer cells can be targeted specifically while protecting healthy tissues because cancer cells frequently have mitochondrial vulnerabilities that are exacerbated when compared to normal cells (70).
- Overcoming therapy resistance: Differential sensitivities to mitochondrial-targeted medicines may be seen in cancer cells with varied mitochondrial populations, offering chances to overcome therapy resistance and enhance treatment results.
- Personalized medicine: By acting as predictors of patient prognosis and response to treatment, mitochondrial biomarkers can help cancer patients receive individualized therapeutic interventions. However, to properly target mitochondrial heterogeneity, several issues need to be resolved:
- Off-target effects: Treatments aimed at the mitochondria may have unintended consequences that impair regular mitochondrial function and cause toxicity.
- Adaptive responses: Cancer cells have the ability to create defense mechanisms to elude treatments that target their mitochondria, which makes the creation of combination tactics necessary to overcome resistance.
- Limited clinical translation: Because of intricate biological interconnections and patient population heterogeneity, bringing mitochondrial-targeted medicines into clinical practice remains difficult, despite encouraging preclinical results.

➢ **Emerging Therapeutic Strategies:** These strategies seek to take advantage of particular weaknesses in the mitochondria of cancer cells, such as:

- Inhibitors of mitochondrial biogenesis: Substances that block the processes leading to mitochondrial biogenesis, such PGC-1α inhibitors, limit the growth and function of mitochondria in cancer cells (71).
- Modulators of mitochondrial quality control: Potential targets for cancer therapy include substances

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

that alter mitochondrial quality control systems including mitophagy and mitochondrial proteostasis (72).

- Mitochondrial DNA-targeted therapies: Techniques like gene editing and mitochondrial DNA repair inhibitors that target mtDNA mutations and maintain the integrity of the mitochondrial genome have potential as precision cancer treatments.

➢ **Methods for Studying Mitochondrial Heterogeneity**

**Visualization Methods for Mitochondrial Heterogeneity Imaging**:

- Confocal Microscopy: This technique allows for the high-resolution observation of the dynamics, shape, and location of mitochondria within cells. MitoTracker and other fluorescent dyes that target mitochondria make it possible to see the structure and function of the mitochondria.
- Super-Resolution Microscopy: Detailed imaging of mitochondrial dynamics and ultrastructure is made possible by super-resolution microscopy methods like as stimulated emission depletion (STED) and stochastic optical reconstruction microscopy (STORM), which offer enhanced spatial resolution.
- Electron microscopy (EM): Examination of mitochondrial morphology and subcellular location is facilitated by transmission electron microscopy (TEM) and scanning electron microscopy (SEM), which provide ultrastructural information about mitochondria at nanoscale resolution.(40)

**Techniques for Molecular Profiling to Examine Mitochondrial Function:**

- High-Throughput Sequencing: Next-generation sequencing (NGS) methods enable thorough characterization of copy number changes, epigenetic modifications, and mutations in mitochondrial DNA (mtDNA) linked to mitochondrial dysfunction in cancer.
- Metabolomics: Metabolite profiling methods allow for the quantitative measurement of mitochondrial metabolites, including as ATP, NADH/NAD+, and Krebs cycle intermediates. Among these techniques are nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry (LC-MS).
- Proteomics and transcriptomics: By providing details on the expression of mitochondrial proteins and gene control, these techniques provide insight on the molecular processes behind mitochondrial heterogeneity and malfunction.(73)

**Models for Investigating Mitochondrial Heterogeneity both In Vitro and In Vivo:**

- Cell Culture Models: Mitochondrial heterogeneity can be studied in vitro using cell lines obtained from various cancer types or patient samples. These models facilitate the modulation of mitochondrial function via pharmacological and genetic manipulations.
- Patient-Derived Xenografts (PDX): These models preserve the genetic and histological features of patient malignancies, offering an in vivo platform for research on mitochondrial heterogeneity. Treatment resistance biomarkers and therapeutic responses can be assessed using PDX models.
- Genetically Engineered Mouse Models (GEMMs): By altering mitochondrial genes or signaling pathways, GEMMs are able to replicate important aspects of the dysfunctional mitochondria seen in human cancers. This facilitates the investigation of the function of mitochondrial heterogeneity in the initiation and advancement of malignancies. (74) Whether applied singly or in combination, these techniques offer insightful information about the genetic and functional aspects of mitochondrial heterogeneity in cancer, which helps to create new approaches for diagnosis and treatment.

**Discussion**

Mitochondria are complicated organelles in which numerous biological processes interact. These processes mediate energy production, cell homeostasis, biomolecule anabolism, mitochondrial biomass modulation, nuclear and mitochondrial genome integrity promotion, and cell viability regulation. The pathological plasticity of mitochondrial functions is critical for the development and progression of cancer.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

For many years, mitochondrial biology has been thoroughly investigated utilizing conventional biochemical and molecular techniques. Our knowledge of mitochondrial biology has drastically changed as a result of technological advancements. The identification of mitochondrial heterogeneity in many cells and tissues is the result of systematic investigations into mitochondrial multi-omics. The chemical mechanisms at play, particularly the intricacy of the mitochondrial genome, are still largely unknown to us. A neutral mtDNA phenotype in one situation could be harmful in another. For clinical research aimed at "clearing up" harmful mtDNA mutations, it is crucial to comprehend the behavior of mtDNA-specific heteroplasmic variations. The thorough characterisation of the mitochondrial protein inventory presents intriguing prospects for the methodical study of this organelle under both healthy and pathological settings in the quickly developing field of mitochondrial proteomics(75).

A comprehensive mitochondrial proteome profile will probably be achieved by combining high-throughput and conventional biochemical techniques to identify hundreds of mitochondrial proteins that are not yet listed in the catalog. The extent of splicing variations and PTMs of each of these proteins, as well as their particular location inside mitochondria, will therefore need to be understood. Understanding how mitochondrial proteins work together in pathways and complexes is a more challenging task with reference to the mitochondrial proteome. The majority of the uncharacterized proteins will be annotated using high-throughput techniques like RNA interference, protein-protein interaction mapping, and computational prediction. The description of mitochondria's heterogeneity in various tissues, developmental stages, and disorders will become more crucial as the protein inventory and complexes of the organelles are improved.

The genetic analysis of both common and uncommon mitochondrial proteome variations is the initial stage in the present characterization of mitochondrial heterogeneity. Large-scale initiatives like the 1000 Genomes Project will soon record the variety of typical mitochondrial genetic variations thanks to next-generation sequencing technologies. Furthermore, resequencing of people with exceptional mitochondrial abnormalities might uncover more high-propensity variations. It is still exceedingly difficult to demonstrate a genetic connection between mitochondrial gene mutations and particular severe traits.

High-resolution mitochondrial proteome data and a technique to target mitochondria are essential for researching the molecular underpinnings of mitochondrial function adaptability and associated changes in various tissues, developmental stages, and illnesses. The multi-omics approach does have several drawbacks, though. First, the mitochondrial proteome may overlook certain genuine mitochondrial proteins because of the limitations of MS-based sequencing, particularly those with unfavorable proteolytic cleavage sites or less than 10 kDa. Second, determining which proteins are present in mitochondria under particular circumstances remains difficult (76).

Mitochondrial heterogeneity-related biomarkers may help with tailored cancer therapy and treatment response prediction. We must take use of new technology, fill in information gaps, and apply creative thinking if we are to improve our understanding of mitochondrial variability and develop new therapeutic targets for cancer treatment. Sustained multidisciplinary research endeavours are vital in order to convert these discoveries into therapeutic advantages for individuals with cancer in clarifying the processes that underlie the heterogeneity of mitochondria in tumors and how it interacts with the surrounding milieu creating cutting-edge technology to investigate single-cell mitochondrial dynamics and function carrying out long-term research to evaluate the clinical applicability of treatment approaches and mitochondrial biomarkers. Investigating combination treatments and precision medicine strategies that make use of knowledge about mitochondrial heterogeneity to treat cancer more successfully.

**Conclusion**

In conclusion, research on mitochondrial heterogeneity in cancer has shed light on how intricate tumor biology is and how it affects how well patients respond to treatment. Because mitochondrial variability affects

cellular metabolism and survival pathways, it plays a role in medication resistance in cancer. As a therapeutic approach, targeting mitochondrial heterogeneity shows promise in overcoming treatment resistance and enhancing patient outcomes.

**Funding and Acknowledgments**: None

**Reference**

1. Munn EA. On the structure of mitochondria and the value of ammonium molybdate as a negative stain for osmotically sensitive structures. J Ultrastruct Res. 1968;25:36280.
2. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359407.
3. Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283:14828.
4. Newmeyer DD, Ferguson-Miller S. Mitochondria: Releasing power for life and unleashing the machineries of death. Cell. 2003;112:48190.
5. Bonawitz ND, Clayton DA, Shadel GS. Initiation and beyond: Multiple functions of the human mitochondrial transcription machinery. Mol Cell. 2006;24:81325.
6. Thyagarajan B, Padua RA, Campbell C. Mammalian mitochondria possess homologous DNA recombination activity. J Biol Chem. 1996;271:27536□43.
7. Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283(5407):1482-8. doi: 10.1126/science.283.5407.1482.
8. Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res. 2002;8(2):481-7. PMID: 11839667.
9. Kumari S, Badana AK, G MM, G S, Malla R. Reactive Oxygen Species: A Key Constituent in Cancer Survival. Biomark Insights. 2018;13:1177271918755391. doi: 10.1177/1177271918755391.
10. Galvan DL, Green NH, Danesh FR. The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int. 2017;92(5):1051-7. doi: 10.1016/j.kint.2017.05.034.
11. Buechter DD. Free radicals and oxygen toxicity. Pharm Res. 1988;5(5):253-60. doi: 10.1023/a:1015914418014.
12. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 2006 May 11;5:14. doi: 10.1186/1477-3163-5-14. PMID: 16689993; PMCID: PMC1479806.
13. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48(2):158-67. doi: 10.1016/j.molcel.2012.09.025.
14. Arakawa S, Nakanomyo I, Kudo-Sakamoto Y, Akazawa H, Komuro I, Shimizu S. Identification of a novel compound that inhibits both mitochondria-mediated necrosis and apoptosis. BiochemBiophys Res Commun. 2015;467(4):1006-11. doi: 10.1016/j.bbrc.2015.10.022.
15. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14(6):575-83. doi: 10.1038/ncb2488.
16. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-905. doi: 10.1038/nature08822.
17. Andersen JL, Kornbluth S. Mcl-1 rescues a glitch in the matrix. Nat Cell Biol. 2012;14(6):563-5. doi: 10.1038/ncb2511.
18. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. CurrOpin Cell Biol. 2010;22(2):263-8. doi: 10.1016/j.ceb.2009.12.003.
19. Gaude E, Frezza C. Defects in mitochondrial metabolism and cancer. Cancer Metab. 2014;2:10. doi: 10.1186/2049-3002-2-10.
20. Sullivan LB, Gui DY, Vander Heiden MG. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer. 2016;16(11):680-93. doi: 10.1038/nrc.2016.85.
21. Dong CK, Masutomi K, Hahn WC. Telomerase: regulation, function and transformation. Crit Rev OncolHematol. 2005;54(2):85-93. doi: 10.1016/j.critrevonc.2004.12.005.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 79-91 | ISSN:2251-6727

22. Muzza M, Colombo C, Cirello V, Perrino M, Vicentini L, Fugazzola L. Oxidative stress and the subcellular localization of the telomerase reverse transcriptase (TERT) in papillary thyroid cancer. Mol Cell Endocrinol. 2016;431:54-61. doi: 10.1016/j.mce.2016.05.005.
23. Singhapol C, Pal D, Czapiewski R, Porika M, Nelson G, Saretzki GC. Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis. PLoS One. 2013;8(1):e52989. doi: 10.1371/journal.pone.0052989.
24. Miwa S, Saretzki G. Telomerase and mTOR in the brain: the mitochondria connection. Neural Regen Res. 2017;12(3):358-61. doi: 10.4103/1673-5374.202202.
25. Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol. 2014;15(10):634-46.
26. Kashatus JA, Nascimento A, Myers LJ, et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell. 2015;57(3):537-51.
27. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47.
28. Guerra F, Kurelac I, Cormio A, et al. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet. 2011;20(13):2394-405.
29. Wang Y, Liu VW, Xue WC, Tsang PC, Cheung AN, Ngan HY. The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. GynecolOncol. 2005;98(1):104-10.
30. Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, Yu SC, Qian GS. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer. 2011;129(4):820-31.
31. Kasahara A, Scorrano L. Mitochondria: from cell death executioners to regulators of cell differentiation. Trends Cell Biol. 2014;24(12):761-70.
32. Gaude E, Frezza C. Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat Commun. 2016;7:13041.
33. Vyas S, Zaganjor E, Haigis MC. Mitochondria and Cancer. Cell. 2016;166(3):555-66.
34. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685-98.
35. Guerra F, Kurelac I, Cormio A, et al. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet. 2011;20(13):2394-405.
36. Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, Yu SC, Qian GS. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer. 2011;129(4):820-31.
37. Kashatus JA, Nascimento A, Myers LJ, et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell. 2015;57(3):537-51.
38. Serasinghe MN, Wieder SY, Renault TT, et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell. 2015;57(3):521-36.
39. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47.
40. Gaude E, Frezza C. Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat Commun. 2016;7:13041.
41. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33(4):207-14.
42. Sonveaux P, V□gran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118(12):3930-42.
43. Bissell MJ, et al. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell. 2005;7:17–23.
44. Begum HM, et al. Spatial regulation of mitochondrial heterogeneity by stromal confinement in micropatternedtumor models. Sci Rep. 2019;9:11187.

45. Rossi M, et al. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. Nature. 2022;605:747–53.
46. Yuan Y, et al. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020;52:342–52.
47. Smith AL, et al. Age-associated mitochondrial DNA mutations cause metabolic remodelling that contributes to accelerated intestinal tumorigenesis. Nat Cancer. 2020;1:976–89.
48. Li N, et al. Mass spectrometry-based mitochondrial proteomics in human ovarian cancers. J Mass Spectrom. 2020;39:471–98.
49. Liu J, et al. Mitochondrial proteomics of nasopharyngeal carcinoma metastasis. [Add publication details if available].
50. Chen M, et al. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines. Cancer Sci. 2015;106:1075–83.
51. Dai Z, et al. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics. 2010;10:3789–99.
52. Li N, et al. The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes. J GynecolOncol. 2018;150:343–54.
53. Chen X, et al. Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer. Theranostics. 2014;4:1164–75.
54. Dahl ES, et al. Targeting IDH1 as a prosenescent therapy in high-grade serous ovarian cancer. Mol Cancer Res. 2019;17:1710–20.
55. Li N, et al. Quantitative analysis of the human ovarian carcinoma mitochondrial phosphoproteome. Aging. 2019;11:6449–68.
56. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
57. Ahn CS, et al. Mitochondria as biosynthetic factories for cancer proliferation. Cell Metab. 2015;3:1.
58. Delaunay S, et al. Mitochondrial RNA modifications shape metabolic plasticity in metastasis. Nature. 2022;607:593–603.
59. Yang J, et al. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.
60. Baysal BE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848–51.
61. Gimenez-Roqueplo AP, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet. 2001;69:1186–97.
62. Frezza C, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011;477:225–8.
63. Porporato PE, et al. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265–80.
64. Heerdt BG, et al. Mitochondrial membrane potential (Δψ(mt)) in the coordination of p53-independent proliferation and apoptosis pathways in human colonic carcinoma cells. Cancer Res. 1998;58:2869–75
65. Heerdt BG, et al. The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res. 2005;65:9861–7.
66. Kuwahara Y, et al. The involvement of mitochondrial membrane potential in cross-resistance between radiation and docetaxel. Int J RadiatOncolBiol Phys. 2016;96:556–65.
67. Lee W, Johnson J, Gough DJ, et al. Mitochondrial DNA copy number is associated with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2019;28(12):1884-91.
68. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015;11(1):9-15.
69. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579-91.
70. Qian W, Choi S, Gibson GA, Watkins SC, Bakkenist CJ, Van Houten B. Mitochondrial hyperfusion induced by loss of the fission protein Drp1 causes ATM-dependent G2/M arrest and aneuploidy through DNA replication stress. J Cell Sci. 2012;125(Pt 23):5745-57.

71. Wanka C, Steinbach JP, Rieger J. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012;287(40):33436-46.
Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev ClinOncol. 2017;14(1):11-31.
72. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685-98.
73. Gaude E, Frezza C. Defects in mitochondrial metabolism and cancer. Cancer Metab. 2014;2(1):10.
74. Pernas L, Scorrano L. Mito-Morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function. Annu Rev Physiol. 2016;78(1):505-31.
75. Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166(3):555-66.
76. Morgenstern M, et al. Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context. Cell Metab. 2021;33:2464–83.e18.